Abstract
Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificity for different types of schizophrenia and potential therapeutic strategies to prevent oxidative injuries in schizophrenia were discussed. Data were extracted from published literature found in Medline, Embase, Biosis, Cochrane and Web of Science, together with hand search of references. Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants and fatty acids. Finding a sensitive, specific and non invasive biomarker of schizophrenia, which could be measured in peripheral tissue, still stays an important task. Antioxidant enzymes, markers of lipid peroxidation, oxidatively modified proteins and DNA are most commonly used. As it considers the supplemental therapy, according to our meta-analysis vitamin E could potentially improve tardive dyskinesia, while for the effect of therapy with polyunsaturated fatty acids there is no clear evidence. Oxidative stress is a part of the pathology in schizophrenia and appears as a promising field to develop new therapeutic strategies. There is a need for well designed, placebo controlled trials with supplementation therapy in schizophrenia.
Keywords: neurotransmitters, maternal malnutrition, Cardinal symptoms, antipsychotics, tardive dyskinesia, biochemical markers, fatty acids, antioxidants, oxidative stress, Schizophrenia
Current Neuropharmacology
Title: Oxidative Stress in Schizophrenia
Volume: 9 Issue: 2
Author(s): Iztok Grabnar, Tomas Vovk, Blanka Kores Plesnicar and Marija Boskovic
Affiliation:
Keywords: neurotransmitters, maternal malnutrition, Cardinal symptoms, antipsychotics, tardive dyskinesia, biochemical markers, fatty acids, antioxidants, oxidative stress, Schizophrenia
Abstract: Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificity for different types of schizophrenia and potential therapeutic strategies to prevent oxidative injuries in schizophrenia were discussed. Data were extracted from published literature found in Medline, Embase, Biosis, Cochrane and Web of Science, together with hand search of references. Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants and fatty acids. Finding a sensitive, specific and non invasive biomarker of schizophrenia, which could be measured in peripheral tissue, still stays an important task. Antioxidant enzymes, markers of lipid peroxidation, oxidatively modified proteins and DNA are most commonly used. As it considers the supplemental therapy, according to our meta-analysis vitamin E could potentially improve tardive dyskinesia, while for the effect of therapy with polyunsaturated fatty acids there is no clear evidence. Oxidative stress is a part of the pathology in schizophrenia and appears as a promising field to develop new therapeutic strategies. There is a need for well designed, placebo controlled trials with supplementation therapy in schizophrenia.
Export Options
About this article
Cite this article as:
Grabnar Iztok, Vovk Tomas, Kores Plesnicar Blanka and Boskovic Marija, Oxidative Stress in Schizophrenia, Current Neuropharmacology 2011; 9 (2) . https://dx.doi.org/10.2174/157015911795596595
DOI https://dx.doi.org/10.2174/157015911795596595 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances in Neuroimaging: Bridging Pharmacology, Nanotechnology, and Neurological Disorders
This special topic seeks to compile cutting-edge research and reviews that explore the synergy between neuroimaging, pharmacology, and nanotechnology in understanding and treating neurological disorders. We aim to elucidate novel imaging biomarkers for tracking drug efficacy and disease progression in conditions such as Alzheimer’s, Parkinson’s, multiple sclerosis, and brain tumors. ...read more
Advances in Neuroinflammation and Neuroprotection: Mechanisms and Therapeutic Frontiers
It offers a comprehensive exploration of neuroinflammatory and neuroprotective pathways that play central roles in a range of neurological disorders, including stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This issue invites research on the cellular and molecular mechanisms driving neuroinflammation, such as the roles of ...read more
Advances in paediatric and adult brain cancers: emerging targets and treatments
Brain tumors are the most common solid tumors affecting children and adolescents, with up to 5,000 children diagnosed per year. Pediatric brain tumors, because of their location, are often untreatable and their clinical management can cause significant long-term impairment to intellectual and neurological function with epilepsy and neurodegeneration. Other than ...read more
Brain and Spinal Cord Injuries
Brain and spinal cord injuries are severe traumatic disorders of the central nervous system (CNS) that can lead to significant sensory and functional deficits, as well as other complications, accompanied by a substantial economic and social burden. Due to the limited regenerative capacity of the CNS, there are currently no ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents The Role of Neurogenesis in Neurodegenerative Diseases and its Implications for Therapeutic Development
CNS & Neurological Disorders - Drug Targets Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Colchicine Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
Current Neuropharmacology The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets CYP-Mediated Clozapine Interactions: How Predictable Are They?
Current Drug Metabolism Breath Analysis: The Approach Towards Clinical Applications
Mini-Reviews in Medicinal Chemistry Role of Vitamin E in Cellular Antioxidant Defense
Current Chemical Biology Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Biomarker Metabolite Signatures Pave the Way for Electronic-nose Applications in Early Clinical Disease Diagnoses
Current Metabolomics Psychotropic Medications and the Treatment of Human Prion Diseases
CNS & Neurological Disorders - Drug Targets Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART I
Current Neuropharmacology L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design Controversies of Dopamine Agonists: Somnolence, Cardiac Valvulopathy and Repetitive Behaviors
Current Drug Therapy Cannabinoids (CBD, CBDHQ and THC): Metabolism, Physiological Effects, Electron Transfer, Reactive Oxygen Species and Medical Use
The Natural Products Journal Aripiprazole in Children and Adolescents with Schizophrenia
Current Psychopharmacology The α2δ Subunit and Absence Epilepsy: Beyond Calcium Channels?
Current Neuropharmacology Effects of Antipsychotics on the BDNF in Schizophrenia
Current Medicinal Chemistry